Data mining coupled to network analysis has been successfully used to study relationships between basic discovery and translational applications such as drug development; and to document research collaborations and knowledge flows. Assembling relevant data for such studies in a form that supports analysis presents challenges. We have developed Enhanced Research Network Information Environment (ERNIE), an open source, scalable cloud-based platform that (i) integrates data drawn from public and commercial sources (ii) provides users with analytical workflows that incorporate expert input at critical stages. A modular design enables the addition, deletion, or substitution of data sources. To demonstrate the capabilities of ERNIE, we have conducted case studies that span drug development and pharmacogenetics. In these studies, we analyze data from regulatory documents, bibliographic and patent databases, research grant records, and clinical trials, to document collaborations and identify influential research accomplishments. measurements of research outputs and research impact has identified challenges 5 and resulted in principles being articulated to guide practice [1, 2, 3, 4, 5] .
Introduction
Measuring progress in research for reporting, planning, and optimization of research programs is of considerable interest to public and private funders, governments, and research organizations. The broader discussion of under the open-source MIT license and are available on GitHub [27] . Table 1 provides an overview of records in the major data sources (excluding records from tables used to process data) in ERNIE. indexes of ERNIE data that can facilitate user searches that return informative, ranked, and scored query results and is the basis for a process that takes advantage of indexed Web of Science publications in ERNIE. A similar approach has been described for citation matching of raw text strings [28] . In our process, a text file containing references is passed as input 120 to a Python script. The user manually selects matching publications from the output hit list that includes citation information, an UT, and the numeric output of the Solr scoring function. In the case of ivacaftor, US7495103, its core patent contained 20 references to scientific publications. Using the manual PubMed approach, 8 of 20 ivacaftor citations were correctly identified.
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Using the Solr indexing approach, 15 of 20 references were correctly identified.
In an extension of this process, selection is also made using a percentile approach, e.g. nth percentile of Solr scores for a given dataset calibrated by 6 scores for known true positive and true negatives. The partially-automated approach process is more scalable and faster than the manual one. A 130 combination of these approaches was used in the case studies described. where a Levenshtein distance of greater than 1 between country name in Web of Science data and the lookup table were managed through ad-hoc scripted corrections, e.g., 'FED REP GER' was converted to 'GERMANY'.
Workflows and Network analysis. For the ipilimumab and ivacaftor case studies, a single generation of cited references was extracted from an input of 145 pmids and/or UTs. The seed set was derived from mining FDA regulatory documents, clinical trials data, patent literature, and bibliographic databases for references that approximately preceded the date of FDA approval for these two drugs. These references were then combined into a citation network where nodes are publications and authors. Grant support, and institutional location 150 are attributes of these nodes. A single verb, 'cites', was used to draw edges between nodes, e.g., node A cites node B. An optional step, availed of in these two cases, was to include the cited references in review articles published within a year of the FDA approval for these drugs. As we have previously noted [13] , the use of pmids for network construction results in significant loss of information, thus we used Web of Science data for network construction. For each article, we calculated in-network citations, as 170 well as weighted citations (sum of article citations plus sum of citations of an article's first degree neighbors). For each author, we calculated the number of articles, total citations and propagated in-degree rank (PIR) [12] .
For the pharmacogenomics case study, we mapped citation paths from the DMET Plus diagnostic panel for drug metabolism to a set of references 175 that define the origins of the DNA microarray technology. We incorporated a combination of references cited b the DMET Plus set and references citing microarray set then generated edgelists and nodelists directly in PostgreSQL and exported the data to the Neo4j graph environment. These data were then analyzed with Cypher queries.
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Visualizations Visualizations were performed using Cytoscape [29] using edgelists and nodelists as input. Edgelists were generated from graph network data as source-target node pairs with additional columns source type (stype) and target type (ttype) that qualify nodes. Node types used in these studies were root, publication (wos id), clinical trial (ct), fda document(fda), author, 185 and patent. An example of a source target pair is provided below that represents the citation of a publication in a patent.
source stype target ttype US7824894 patent WOS:A1996UX51900025 wos id
Results and Discussion
Ipilimumab and ivacaftor 190 To establish a baseline for content and to validate our workflow, the FDA-approved therapeutics ipilimumab and ivacaftor were selected as case studies since they have previously been studied [12] . Williams Although we recorded many more researchers in these two networks, the for ivacaftor are found in our list of researchers. However, the two lists are not 210 identically ordered. For example, 50% of the top 10 researchers in our ipilimumab set overlap with the top 10 in the Williams dataset. We attribute these differences to improved harvesting of references and richer content of the data in ERNIE and suggest that the use of bins is likely to be more useful than individual rank order comparisons in identifying elite performers. 215 We observed instances of missing author address data from the To identify influential publications, we calculated a weighted citation score for each node in these networks [12, 13] , which consists of in-network 225 citations to each node summed with in-network citations of its first degree neighbors. These data are shown in Figure 3 as maximum, minimum, and average values of all publications in a given year. In a variant of the approach used to study ipilimumab and ivacaftor, we also conducted case studies on buprenorphine and naltrexone, drugs used in 230 the treatment of substance abuse (Supplementary material). For these two case studies, the seed sets were assembled by a simple keyword search in PubMed followed by extraction of a generation of cited references. The resultant network was analyzed for acknowledgment of grant support from NIH.
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Citation Pathways
Microarray technology has had considerable impact in biomedical research. A keyword search for 'microarray' in 2018 using PubMed yields more than 86,000 references, testifying to its remarkable impact that has been documented in historiographic studies from various perspectives [30, 31, 32] .
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The technology has since been applied to pharmacogenomics, and diagnostic kits are now available to used to predict phenotypes in drug metabolism [33] based on polymorphisms in cytochrome P450 genes.
To study the evolution of this application of microarray technology, we assembled a dataset in the PostgreSQL environment and exported it to a graph 245 database environment to facilitate analysis. We constructed traces of citations between nine publications representing the origin of the technology [16, 17, 18] dating from 1991 and earlier, to 28 references defining the more recently developed DMET Plus [15] diagnostic kit. From the microarray references, two successive generations of citing references were extracted using Web of Science 250 data. From the diagnostic references, two successive generations of references were extracted. The data were combined and exported into the Neo4j graph database to create a graph with 394,544 documents represented as nodes.
The PageRank algorithm has been used to identify influential publications in citation networks including those described as 'gems' [34] and 255 has the theoretical advantage of considering all nodes in a network when scoring as compared to our weighted citation approach that considers only first degree neighbors. Thus, each node was annotated with PageRank scores, as well as acknowledgement of grant support from NIH institutes. Paths were traced from all nodes in the microarray set to all nodes in the diagnostic set 260 using the allShortestPaths function in Neo4j. Additional constraints were also applied to count shortest paths that traversed at least one node in the 90th percentile of PageRank scores for this distribution and/or at least one node acknowledging NIH support. These enabled identification of paths that passed through at least one highly influential node that included support from NIH.
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The results are summarized in Table 3 process supports expert judgment. The ERNIE paradigm is intended to support distributed access, curation, and ownership of evaluation datasets.
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Smaller evaluation teams unable to afford commercial services may be able to work with subsets of the content in ERNIE, e.g., PubMed alone instead of PubMed and Web of Science and modify the code and workflows to their own needs. We are exploring other linking approaches based on text similarity.
We also provide initial observations in these case studies that can be 295 extended through new analytical approaches and additional data sources. We do not claim that these studies are complete. One limitation is incomplete data on funding; we focused on NIH because of its very large spending on biomedical research and the availability of its funding records but significant spending by other funders is not accounted for. This limitation could be 300 addressed in part by improved extraction from Web of Science data, which contains information on other funders. An alternative is subscription to a commercially available source of information on funding. A second limitation is that the results from our case studies are largely descriptive, which may be appropriate for an article focused on demonstrating features of a data 305 repository. However, it is also important to rigorously analyze these datasets further and we have ongoing efforts in this regard. A third caveat is the focus on citations, which have their own limitations [2, 7] . Our case studies themselves would be more informative if conducted in close collaboration with the policy community to help refine the questions to be asked and interpret 310 the results using expert judgment. 
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